This study is in progress, not accepting new patients
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Summary
- Eligibility
- for people ages 16-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Melvin Heyman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Melvin Heyman
Professor Emeritus, Pediatrics, School of Medicine. Authored (or co-authored) 334 research publications. Research interests: inflammatory bowel disease (ulcerative colitis · Crohn's disease) · Pediatric Nutrition · Pancreatitis in children (acute and chronic) · Mentoring and Career Development · Fellowship Training · Gastroesophageal Reflux Disease
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT03105102
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1336 people participating
- Last Updated